LobbyingMadrigal Pharmaceuticals lobbying by quarter
Madrigal Pharmaceuticals MDGL's latest lobbying report covers Q2 2026, at $610K. The four quarters Q4 2025–Q3 2026 total $1.7M. Its first report covers Q4 2024; the issues it reports most are Health Issues and Medicare/Medicaid.
Madrigal PharmaceuticalsMDGL
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1.7M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2024 | $60K | 1 |
| Q1 2025 | $60K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $110K | 3 |
| Q4 2025 | $450K | 4 |
| Q1 2026 | $610K | 4 |
| Q2 2026 | $610K | 4 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$935K · 14 reports
- Medicare and Medicaid$665K · 9 reports
- Pharmacy$240K · 2 reports
- Medical research and clinical labs$40K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES11 reports
- SENATE10 reports
- Health & Human Services, Dept of (HHS)2 reports
- U.S. Trade Representative (USTR)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseMadrigal Pharmaceuticals | $1.1M | 4 quarters |
| Ballard Partners | $320K | 3 quarters |
| Thorn Run Partners | $280K | 5 quarters |
| Crossroads Strategies | $170K | 4 quarters |
| Capitol Counsel | $120K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ALISON ANWAY | LA to Senator Pat Roberts 2006-2010 | Q2 2026 |
| ELI KOGAN | Sr. Legislative Assistant; Legislative Assistant; Legislative Aide; Legislative Correspondent - Representative Joe Crowley | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $380K |
| 07/19for Q2 | Crossroads Strategies | $50K |
| 07/16for Q2 | Capitol Counsel | $60K |
| 07/15for Q2 | Ballard Partners | $120K |
| 04/24for Q1 | In-house | $380K |
| 04/20for Q1 | Crossroads Strategies | $50K |
| 04/18for Q1 | Capitol Counsel | $60K |
| 04/16for Q1 | Ballard Partners | $120K |
| 02/18for Q1 | Capitol Counsel | Under $5,000 |
| 01/22for Q4 2025 | In-house | $280K |
| 01/20for Q4 2025 | Crossroads Strategies | $50K |
| 01/19for Q4 2025 | Thorn Run Partners | $40K |
| 01/14for Q4 2025 | Ballard Partners | $80K |
| 01/14for Q4 2025 | Ballard Partners | $60K |
| 25/12/09for Q4 2025 | Ballard Partners | Under $5,000 |
| 25/12/04for Q3 2025 | In-house | $30K |
| 25/10/20for Q3 2025 | Thorn Run Partners | $60K |
| 25/10/19for Q3 2025 | Crossroads Strategies | $20K |
| 25/10/07for Q3 2025 | In-house | Under $5,000 |
| 25/10/06for Q3 2025 | Crossroads Strategies | Under $5,000 |